Zhu, F.; Huang, T.; Jin, P.; Zhang, L.; Jin, Z.; Zhang, W.; Yuan, D.; Wang, Z.; Deng, Y.; Li, J.;
et al. Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Vaccines 2025, 13, 43.
https://doi.org/10.3390/vaccines13010043
AMA Style
Zhu F, Huang T, Jin P, Zhang L, Jin Z, Zhang W, Yuan D, Wang Z, Deng Y, Li J,
et al. Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Vaccines. 2025; 13(1):43.
https://doi.org/10.3390/vaccines13010043
Chicago/Turabian Style
Zhu, Fengcai, Ting Huang, Pengfei Jin, Linglin Zhang, Zhongqiang Jin, Wenli Zhang, Dongya Yuan, Zhong Wang, Yusong Deng, Jiaxin Li,
and et al. 2025. "Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial" Vaccines 13, no. 1: 43.
https://doi.org/10.3390/vaccines13010043
APA Style
Zhu, F., Huang, T., Jin, P., Zhang, L., Jin, Z., Zhang, W., Yuan, D., Wang, Z., Deng, Y., Li, J., Shen, X., Fu, Y., Li, J., Yang, X., Li, J., & Xie, L.
(2025). Safety and Immunogenicity of the Tetravalent Recombinant COVID-19 Protein Vaccine SCTV01E in Children and Adolescents Aged 3 to 17 Years: A Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Trial. Vaccines, 13(1), 43.
https://doi.org/10.3390/vaccines13010043
